We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Random Plasma Glucose Tests Could Predict Diabetes

By LabMedica International staff writers
Posted on 30 Jul 2019
Print article
Image: New research suggests random plasma blood glucose tests can identify diabetes patients (Photo courtesy of Chris Hannemann).
Image: New research suggests random plasma blood glucose tests can identify diabetes patients (Photo courtesy of Chris Hannemann).
Diabetes is a major health problem in the USA, yet over seven million Americans with diabetes go undiagnosed. Diabetes is the major cause of kidney failure, blindness, and non-traumatic leg amputations in adults in the USA and a leading cause of stroke and heart disease.

Early diagnosis allows the use of lifestyle changes or medications that could help prevent or delay the progression from prediabetes to diabetes and help keep diabetes from worsening. When diagnosis is delayed, diabetes-related complications could develop before treatment starts.

A team of scientists working with the Emory University School of Medicine (Atlanta, GA, USA) conducted a retrospective analysis of the association of outpatient random plasma glucose (RPG) levels with the subsequent clinical diagnosis of diabetes. Study subjects were veterans with data in the Veterans Administration (VA) Informatics and Computing Infrastructure (VINCI) Corporate Data Warehouse (CDW).

The team selected veterans who (a) did not have a diabetes diagnosis during a baseline year (365 days) in 2002–2007; (b) had three or more measurements of random plasma/serum glucose (RPG) during the baseline year, along with assessments of other demographic variables and cardiovascular disease (CVD) risk factors; and (c) had subsequent continuity of primary care [≥1 primary care provider (PCP) visit per year for five years immediately following the baseline year].

The scientists reported that over a five-year follow-up, about 10% of the total study group developed diabetes. Elevated random plasma glucose levels, though not meeting the diagnostic threshold for diabetes, accurately predicted the development of diabetes within the following five years. Patients with at least two random plasma glucose measurements of 115 mg/dL or higher within a 12-month period were highly likely to be diagnosed with diabetes within a few years. Glucose levels of 130 mg/dL or higher were even more predictive of diabetes. Development of diabetes was infrequent in subjects whose highest random plasma glucose levels were below 110 mg/dL.

The authors recommended that patients receive follow-up diagnostic testing for diabetes, such as a fasting glucose or HbA1c test, if they have two random glucose tests showing levels of 115 mg/dL or higher. This approach would very likely be cost-effective, they say, because clinicians can use testing that is already being done during routine outpatient visits. Using random glucose levels for screening could identify patients at higher risk for diabetes, leading to earlier intervention to prevent or control the disease. The study was published on July 19, 2019, in the journal PLOS ONE.”

Related Links:
Emory University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.